tetano
Editor, Senior Moderator
Nature
2020 May 26.
doi: 10.1038/s41586-020-2381-y. Online ahead of print.
A Human Neutralizing Antibody Targets the Receptor Binding Site of SARS-CoV-2
Rui Shi[SUP] 1 2 [/SUP], Chao Shan[SUP] 3 [/SUP], Xiaomin Duan[SUP] 1 2 [/SUP], Zhihai Chen[SUP] 4 [/SUP], Peipei Liu[SUP] 5 [/SUP], Jinwen Song[SUP] 6 [/SUP], Tao Song[SUP] 1 7 8 [/SUP], Xiaoshan Bi[SUP] 1 9 [/SUP], Chao Han[SUP] 1 2 [/SUP], Lianao Wu[SUP] 9 10 [/SUP], Ge Gao[SUP] 3 [/SUP], Xue Hu[SUP] 3 [/SUP], Yanan Zhang[SUP] 3 [/SUP], Zhou Tong[SUP] 1 10 [/SUP], Weijin Huang[SUP] 11 [/SUP], William Jun Liu[SUP] 5 [/SUP], Guizhen Wu[SUP] 5 [/SUP], Bo Zhang[SUP] 3 [/SUP], Lan Wang[SUP] 11 [/SUP], Jianxun Qi[SUP] 10 12 [/SUP], Hui Feng[SUP] 13 [/SUP], Fu-Sheng Wang[SUP] 14 [/SUP], Qihui Wang[SUP] 15 16 [/SUP], George Fu Gao[SUP] 17 [/SUP], Zhiming Yuan[SUP] 18 [/SUP], Jinghua Yan[SUP] 19 20 21 [/SUP]
Affiliations
Abstract
An outbreak of the coronavirus disease 2019 (COVID-19)[SUP]1-3[/SUP], caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SUP]4[/SUP] spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition, CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the virus/receptor interactions by both steric hindrance and direct interface-residue competition. Our results suggest CB6 deserves further clinical translation.
2020 May 26.
doi: 10.1038/s41586-020-2381-y. Online ahead of print.
A Human Neutralizing Antibody Targets the Receptor Binding Site of SARS-CoV-2
Rui Shi[SUP] 1 2 [/SUP], Chao Shan[SUP] 3 [/SUP], Xiaomin Duan[SUP] 1 2 [/SUP], Zhihai Chen[SUP] 4 [/SUP], Peipei Liu[SUP] 5 [/SUP], Jinwen Song[SUP] 6 [/SUP], Tao Song[SUP] 1 7 8 [/SUP], Xiaoshan Bi[SUP] 1 9 [/SUP], Chao Han[SUP] 1 2 [/SUP], Lianao Wu[SUP] 9 10 [/SUP], Ge Gao[SUP] 3 [/SUP], Xue Hu[SUP] 3 [/SUP], Yanan Zhang[SUP] 3 [/SUP], Zhou Tong[SUP] 1 10 [/SUP], Weijin Huang[SUP] 11 [/SUP], William Jun Liu[SUP] 5 [/SUP], Guizhen Wu[SUP] 5 [/SUP], Bo Zhang[SUP] 3 [/SUP], Lan Wang[SUP] 11 [/SUP], Jianxun Qi[SUP] 10 12 [/SUP], Hui Feng[SUP] 13 [/SUP], Fu-Sheng Wang[SUP] 14 [/SUP], Qihui Wang[SUP] 15 16 [/SUP], George Fu Gao[SUP] 17 [/SUP], Zhiming Yuan[SUP] 18 [/SUP], Jinghua Yan[SUP] 19 20 21 [/SUP]
Affiliations
- PMID: 32454512
- DOI: 10.1038/s41586-020-2381-y
Abstract
An outbreak of the coronavirus disease 2019 (COVID-19)[SUP]1-3[/SUP], caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SUP]4[/SUP] spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-19 patient. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro against SARS-CoV-2. In addition, CB6 inhibited SARS-CoV-2 infection in rhesus monkeys at both prophylactic and treatment settings. Further structural studies revealed that CB6 recognizes an epitope that overlaps with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 receptor binding domain (RBD), thereby interfering with the virus/receptor interactions by both steric hindrance and direct interface-residue competition. Our results suggest CB6 deserves further clinical translation.